CINECA IRIS Institutional Research Information System

NUTI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.101
AS - Asia 6.016
EU - Europa 3.911
SA - Sud America 725
AF - Africa 202
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 20.968
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.788
HK - Hong Kong 1.966
SG - Singapore 1.500
CN - Cina 1.471
IT - Italia 1.408
BR - Brasile 615
DE - Germania 534
SE - Svezia 533
BG - Bulgaria 361
GB - Regno Unito 282
VN - Vietnam 282
TR - Turchia 254
CA - Canada 235
IN - India 150
FR - Francia 149
RU - Federazione Russa 145
FI - Finlandia 143
UA - Ucraina 114
SN - Senegal 67
JP - Giappone 52
BD - Bangladesh 51
AT - Austria 48
KR - Corea 48
AR - Argentina 47
MX - Messico 40
IQ - Iraq 38
CH - Svizzera 34
NG - Nigeria 33
BE - Belgio 31
ZA - Sudafrica 30
ID - Indonesia 28
SA - Arabia Saudita 27
PK - Pakistan 25
ES - Italia 24
NL - Olanda 18
CO - Colombia 16
PL - Polonia 16
VE - Venezuela 15
EC - Ecuador 14
MA - Marocco 14
TW - Taiwan 13
KE - Kenya 12
UZ - Uzbekistan 12
CI - Costa d'Avorio 11
CZ - Repubblica Ceca 11
GR - Grecia 11
JM - Giamaica 10
MY - Malesia 10
IR - Iran 9
LT - Lituania 9
AE - Emirati Arabi Uniti 8
IE - Irlanda 8
IL - Israele 8
TT - Trinidad e Tobago 8
AZ - Azerbaigian 7
DK - Danimarca 7
DZ - Algeria 7
JO - Giordania 7
KZ - Kazakistan 7
PY - Paraguay 7
KG - Kirghizistan 6
LB - Libano 6
PH - Filippine 6
AU - Australia 5
BB - Barbados 5
EG - Egitto 5
ET - Etiopia 5
NP - Nepal 5
PS - Palestinian Territory 5
UY - Uruguay 5
AL - Albania 4
BJ - Benin 4
CL - Cile 4
DO - Repubblica Dominicana 3
HR - Croazia 3
HU - Ungheria 3
PA - Panama 3
SY - Repubblica araba siriana 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
BW - Botswana 2
CG - Congo 2
EU - Europa 2
LV - Lettonia 2
ME - Montenegro 2
MO - Macao, regione amministrativa speciale della Cina 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PR - Porto Rico 2
PT - Portogallo 2
RS - Serbia 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A1 - Anonimo 1
AM - Armenia 1
BH - Bahrain 1
BM - Bermuda 1
CR - Costa Rica 1
Totale 20.947
Salva come PNG Salva come JPEG
Città #
Hong Kong 1.954
Woodbridge 1.068
Ashburn 1.009
Ann Arbor 910
Singapore 840
Chandler 725
Houston 697
Fairfield 688
Santa Clara 558
Dallas 505
Sofia 361
Shanghai 349
Serra 332
Beijing 327
Seattle 296
Milan 281
Wilmington 268
New York 249
Cambridge 216
Ottawa 191
Boardman 177
Princeton 173
Izmir 163
Los Angeles 158
Jacksonville 139
Lawrence 138
Nanjing 122
Medford 120
Florence 119
London 116
Des Moines 107
Bremen 93
Hefei 80
Dong Ket 78
Dakar 67
Istanbul 66
Pisa 62
Frankfurt am Main 54
Redondo Beach 54
São Paulo 53
Munich 51
Buffalo 50
Ho Chi Minh City 43
Marseille 41
Nanchang 41
Seoul 40
Tokyo 39
Rome 38
Vienna 38
Council Bluffs 37
Redwood City 37
Dearborn 35
Hanoi 31
Hebei 31
Lagos 31
Livorno 30
San Diego 30
Bern 29
Brussels 29
Ogden 28
Pune 27
The Dalles 27
Lancaster 26
Lucca 26
Gif-sur-Yvette 25
Kunming 25
Changsha 24
Pessac 24
Rio de Janeiro 24
Boulder 23
Nürnberg 23
Columbus 22
Belo Horizonte 21
Baghdad 20
Shenyang 20
Alessandria 19
Guangzhou 19
Jüchen 18
Turku 18
Jiaxing 17
Norwalk 17
Auburn Hills 16
San Francisco 16
Toronto 16
Chicago 15
Tianjin 15
Hangzhou 14
Johannesburg 14
Viareggio 14
Dhaka 13
Falls Church 13
Fuzhou 13
Washington 13
Chennai 12
Nuremberg 12
San Jose 12
Abidjan 11
Denver 11
Jakarta 11
Nairobi 11
Totale 15.409
Salva come PNG Salva come JPEG
Nome #
Strategies to target ADAM17 in disease: From its discovery to the iRhom revolution 1.260
N-(aroyl)-N-(arylmethyloxy)-α-alanines: selective inhibitors of aldose reductase 221
Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization 205
ADAMs and ADAMTs selective synthetic inhibitors 204
Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies 193
ADAM metalloproteinases as potential drug targets 191
Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate-Benzenesulfonamide Conjugates 189
INHIBITORS OF ZINC PROTEASES THIOARYL SUBSTITUTED AND THEIR USE 186
Design and Synthesis of Ionic Liquid-Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI-Coated Gold Nanoparticles 184
Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors 183
Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates 183
Synthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compounds 182
Benzo[d]isothiazoles and Matrix Metalloproteinases. Searching for Novel and Selective Inhibitors of MMP9 180
Ionic liquid-promoted green synthesis of biologically relevant diaryl thioethers 179
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides 178
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity 177
Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide 174
Age-related macular degeneration: Current knowledge of zinc metalloproteinases involvement 174
Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors 173
Activation of carbonic anhydrases from human brain by amino alcohol oxime ethers: towards human carbonic anhydrase VII selective activators 172
Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell Models 170
A new D2 dopamine receptor agonist allosterically modulates A2A adenosine receptor signalling by interacting with the A2A/D2 receptor heteromer 170
N-O-Isopropyl sulfonamido-based hydroxamates: Kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors 169
N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis 167
Synthetic MMP Inhibitors: Slow-Binding Behaviour of Enantioselective N-O-Sulfonamido Based Inhibitors Directed to Specific Matrixins 166
Crystallization of bi-functional ligand protein complexes 166
Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation. 165
Drug design of sulfonylated MMP inhibitors 164
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) 164
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors 164
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs 163
Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor-a Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell Models 163
New bifunctional metalloproteinase inhibitors: an integrated approach towards biological improvements and cancer therapy. 163
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP) 163
Immobilization of matrix metalloproteinase 8 (MMP-8) for online drug screening 162
Synthesis of New Classes of MMPs Sugars-Based Inhibitors 162
Synthetic analogs of xanthohumol for use in the prevention and​/or treatment of tumors 162
Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 Inhibitors 162
Matrix metalloproteinase inhibitors prevent the release and proteolytic activity of monocyte/macrophage-derived microparticles 162
Aryl-sulphonamidic dimers as metalloproteases inhibitors 158
Arylsulfonamide derivatives as metalloproteases inhibitors and their preparation, pharmaceutical compositions and use in the treatment of degenerative disorders 158
In Vivo Imaging of Matrix Metalloproteinase 12 and Matrix Metalloproteinase 13 Activities in the Mouse Model of Collagen-Induced Arthritis 157
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: Enantioselective synthesis and selective inhibition of MMPs 156
Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors 154
MMP-8 Is Critical for Dexamethasone Therapy in Alkali-Burned Corneas Under Dry Eye Conditions 152
Multitemplate Alignment Method for the Development of a Reliable 3D-QSAR Model for the Analysis of MMP3 Inhibitors 151
Design of selective collagenase 3 (MMP-13) inhibitors as potential therapeutic agents in rheumatoid arthritis 150
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP 150
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors 149
Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues 149
Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity 148
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma 145
Analysis of Human Carbonic Anhydrase II: Docking Reliability and Receptor-Based 3D-QSAR Study 144
Powerful twin carboxylic inhibitors for MMP homodimerization 142
Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models 142
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases 141
Bacterial Zinc Metalloenzyme Inhibitors: Recent Advances and Future Perspectives 140
Structural Insights on Carbonic Anhydrase Inhibitory Action, Isoform Selectivity, and Potency of Sulfonamides and Coumarins Incorporating Arylsulfonylureido Groups 140
Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect 139
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates 138
Design, synthesis, biological evaluation and NMR studies of a new series of arylsulfones as selective and potent MMP-12 inhibitors 138
Amino Acid Derivatives as New Zinc Binding Groups for the Design of Selective Matrix Metalloproteinase Inhibitors 137
Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors 137
1-(PHENYLSULPHONAMIDO)-PYRAZOLE DERIVATIVES AS CARBONIC ANHYDRASE INHIBITORS. 136
A new small molecule, D2 dopamine receptor agonist, as an allosteric modulator of A2A adenosine receptor signalling 134
Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes 134
Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition 133
Arylsulfonamido compounds as metalloprotease inhibitors and their preparation, pharmaceutical compositions and use as diagnostic as well as radiotherapeutic agents 133
Compounds with a benzo [a]carbazole structure for use in the prevention and/or treatment of infectious diseases 132
Synthesis and Preliminary Evaluation in Tumor Bearing Mice of New 18F‑Labeled Arylsulfone Matrix Metalloproteinase Inhibitors as Tracers for Positron Emission Tomography 132
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF NEW 7BETA-(BENZO[A]DIHYDROCARBAZOLYLOXYACETYL)-SUBSTITUTED CEPHALOSPORINS 131
NMR STUDIES OF A NEW POTENT MMP-12 INHIBITOR: INSIGHT INTO KEY BINDING INTERACTIONS 128
Design, synthesis, biological evaluation and NMR studies of a new series of arylsulfones as selective and potent MMP-12 inhibitors 128
Metalloprotease inhibitor profiles of human ADAM8 in vitro and in cell-based assays 128
Novel Peptidomimetic as MMP-2 Inhibitors 126
Synthetic MMP Inhibitors: Slow-Binding Behaviour of Enantioselective N-O-Sulfonamido Based Inhibitors Directed to Specific Matrixins 126
Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: Solution and X-ray crystallographic studies 124
Inhibition of pseudolysin and thermolysin by hydroxamate-based MMP inhibitors 122
Effects of selective MMP-2 inhibitors on viability and invasiveness in the U87MG human glioblastoma cell line 121
Design of Selective Collagenase 3 (MMP-13) Inhibitors as Potential Therapeutic Agents in Rheumatoid Arthritis 119
Molecular Underpinnings of MMP-13 Selective Inhibition by Arylsulfonamido Hydroxamate Analogues as Potential Therapeutic Agents in Osteoarthritis 118
Tricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit a- and ß-Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 Isoforms 118
New chromane, thiocromane and tetrahydronaphtalene oxime ether derivatives combining SERT and a2-adrenoceptor affinity 118
Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis 118
Discovery of a new subnanomolar Tumor Necrosis Factor-alpha Converting Enzyme (TACE) inhibitor as antiinvasive agent 117
A new small molecule, D2 dopamine receptor agonist, as an allosteric modulator of A2A adenosine receptor signalling 117
null 116
Design, Synthesis and Inhibitory Properties of Potent Sulfonyl Diaryl Based MMPs and TACE inhibitors 116
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: A first round of lead optimization 115
Targeting ADAM17 Sheddase Activity in Cancer 115
D2 dopamine receptor agonists as allosteric modulators of A2A adenosine receptor signalling 114
Arylsulfonamide derivatives, especially dimeric hydroxamic acid-​containing amino acids, metalloproteases inhibitors and their preparation, pharmaceutical compositions and use in the treatment of degenerative disorders 114
Design, synthesis and biological properties of new potent and selective sulfonamide-based inhibitors of gelatinase A 111
New 18F-Labelled Inhibitors of Matrix Metalloproteinases as Imaging Probes for PET Imaging 108
Bivalent Inhibitor with Selectivity for Trimeric MMP-9 Amplifies Neutrophil Chemotaxis and Enables Functional Studies on MMP-9 Proteoforms 107
Design, synthesis and biological evaluation of arylsulfonamides as ADAMTS7 inhibitors 106
Sintesi e Valutazione Biologica di Acidi Aril-Solfonil-Fosfonici come Inibitori Selettivi delle Metalloproteinasi di Matrice (MMP) 106
Analoghi sintetici dello xantumolo 106
Identification of broad-spectrum mmp inhibitors by virtual screening 106
Inhibition of matrix degrading enzymes and invasion in rat glioblastoma (C6) cells 105
Totale 15.868
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.194
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.194
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021767 0 0 0 0 0 135 52 101 116 90 62 211
2021/20221.590 30 179 34 63 287 218 46 74 49 40 85 485
2022/20232.238 251 270 147 283 236 266 13 166 403 11 151 41
2023/20241.466 163 137 149 93 192 292 72 69 24 33 112 130
2024/20254.481 27 180 95 260 460 402 419 247 431 569 424 967
2025/20264.268 407 1.855 650 426 557 373 0 0 0 0 0 0
Totale 21.316